Thank you.
I have a quick question for Mr. Warner.
We know that the TRIPS waiver doesn't solve the problem. Passing this IP to any given third party isn't going to solve the problem, because you still need the raw material, which could be very exclusive to certain places, certain countries and certain companies. If, at the end of the day, you cannot pass the IP to be able to produce locally and to increase the production capacity, that is fine. If you're going to aim to reduce the price per dose, this is another issue.
How do you see that dynamic?